Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 6
2021 7
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658.
Madariaga A, Bhat G, Wilson MK, Li X, Cyriac S, Bowering V, Hunt W, Gutierrez D, Bonilla L, Kasherman L, McMullen M, Wang L, Ghai S, Dhani NC, Oza AM, Lheureux S. Madariaga A, et al. Among authors: mcmullen m. Am J Obstet Gynecol. 2024 Apr 27:S0002-9378(24)00475-7. doi: 10.1016/j.ajog.2024.03.039. Online ahead of print. Am J Obstet Gynecol. 2024. PMID: 38679558 No abstract available.
Advances in ovarian cancer, from biology to treatment.
McMullen M, Karakasis K, Rottapel R, Oza AM. McMullen M, et al. Nat Cancer. 2021 Jan;2(1):6-8. doi: 10.1038/s43018-020-00166-5. Nat Cancer. 2021. PMID: 35121897 No abstract available.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Cohen PA, et al. Among authors: mcmullen m. Int J Gynecol Cancer. 2022 Apr 4;32(4):560-565. doi: 10.1136/ijgc-2021-002999. Int J Gynecol Cancer. 2022. PMID: 34551895 Clinical Trial.
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences.
Madariaga A, Bhat G, Wilson MK, Li X, Cyriac S, Bowering V, Hunt W, Gutierrez D, Bonilla L, Kasherman L, McMullen M, Wang L, Ghai S, Dhani NC, Oza AM, Lheureux S. Madariaga A, et al. Among authors: mcmullen m. Am J Obstet Gynecol. 2021 Dec;225(6):658.e1-658.e9. doi: 10.1016/j.ajog.2021.06.071. Epub 2021 Jun 23. Am J Obstet Gynecol. 2021. PMID: 34174204
A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers.
Cook AM, McDonnell A, Millward MJ, Creaney J, Hasani A, McMullen M, Meniawy T, Robinson BWS, Lake RA, Nowak AK. Cook AM, et al. Among authors: mcmullen m. Expert Rev Anticancer Ther. 2021 May;21(5):465-474. doi: 10.1080/14737140.2021.1882308. Epub 2021 Feb 9. Expert Rev Anticancer Ther. 2021. PMID: 33509005 Clinical Trial.
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. McMullen M, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2. Int J Gynecol Cancer. 2020. PMID: 32878963 Free PMC article.
16 results